A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

• ClinicalTrials.gov Identifier: NCT04647344
• Recruitment Status: Not yet recruiting
• First Posted: November 30, 2020
• Last Update Posted: November 30, 2020
• Sponsor: Akeso
• Information provided by (Responsible Party): Akeso

Study Description

Brief Summary:

This is a phase Ib/II , open-label, multicenter single arm study designed to evaluate the efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of AK104 combined with Carboplatin and Pemetrexed/ Paclitaxel as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer.

Condition or disease	Intervention/treatment	Phase
Lung Cancer Non-Small Cell Stage IIIB/IIIC/IV	Drug: AK104 plus Carboplatin and Pemetrexed; Drug: AK104 plus Carboplatin and paclitaxel	Phase 1; Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 60 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: An Open-label, Multicenter, Phase Ib/II Study of AK104, Combined Chemotherapy as First-line Therapy to Treat Locally Advanced or Metastatic Non-small Cell Lung Carcinoma
• Estimated Study Start Date: November 20, 2020
• Estimated Primary Completion Date: February 8, 2023
• Estimated Study Completion Date: April 8, 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: Nonsquamous NSCLC	Drug: AK104 plus Carboplatin and Pemetrexed; Subjects receive AK104 15mg/kg intravenously (IV) plus pemetrexed 500 mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK104 15mg/kg IV plus pemetrexed 500 mg/m^2 IV Q3W until progression.
Experimental: Squamous NSCLC	Drug: AK104 plus Carboplatin and paclitaxel; Subjects receive AK104 15mg/kg intravenously (IV) plus paclitaxel 175 mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK104 15mg/kg IV IV Q3W until progression.

Outcome Measures

Primary Outcome Measures :

1. The number of subjects experiencing adverse events (AEs) (Phase Ib) [ Time Frame: From the time of informed consent through 90 days following termination of treatment with investigational product ]
2. Objective response rate (ORR) assessed by investigator [ Time Frame: Up to 2 years ]

Secondary Outcome Measures :

1. Disease control rate (DCR) [ Time Frame: Up to 2 years ]
2. Duration of response (DoR) [ Time Frame: Up to 2 years ]
3. Progression-free survival (PFS) [ Time Frame: Up to 2 years ]
4. Overall survival (OS) [ Time Frame: Up to 2 years ]
5. Time to response (TTR) [ Time Frame: Up to 2 years ]
6. Minimum observed concentration (Cmin) of AK104 at steady state [ Time Frame: From first dose of AK104 through 90 days after last dose of AK104 ]
7. Number of subjects who develop detectable anti-drug antibodies (ADAs) [ Time Frame: From first dose of AK104 through 90 days after last dose of AK104 ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Signed written informed consent form voluntarily.
• Age over 18 years old (inclusive) and not more than 75 years old (inclusive), when signing the informed consent form.
• Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.
• Expected life expectance ≥ 3 months.
• Histologically or cytologically confirmed diagnosis of locally advanced or metastatic NSCLC.
• No prior systemic chemotherapy for advanced or metastatic NSCLC. Subjects who have received prior adjuvant chemotherapy or neoadjuvant chemotherapy with curative intent, or definitive chemoradiotherapy for advanced disease, will be eligible provided that progression has occurred >6 months from last treatment.
• At least one measurable tumor lesion per RECIST 1.1 criteria. A lesion previously irradiated will not be considered a target lesion.
• Subjects must provide an available tumor tissue sample taken < 1 year prior to first dose of study treatment.
• Subjects must provide wild-type epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) reported by tissue-based tests（for non-squamous NSCLC subjects only）.
• Adequate organ function.
• Females of childbearing potential who are sexually active with a nonsterilized male partner must use at least one highly effective method of contraception.
• nonsterilized males who are sexually active with a female partner of childbearing potential must use highly effective method of contraception from Day 1 and for 120 days after the last dose of investigational product.

Key Exclusion Criteria:

• Subjects who are diagnosed as NSCLC that harbors an epidermal growth factor receptor (EGFR)-sensitizing mutation or anaplastic lymphoma kinase (ALK) gene translocation.
• Mixed tumors will be categorized by the predominant cell type; if small cell elements are present, the subject is ineligible
• Received prior treatment with EGFR inhibitors or ALK inhibitors.
• Is currently participating intervention study or has participated in a study of an investigational agent or investigational device within 4 weeks prior to administration of AK104.
• Prior exposure to any anti-PD-1, anti-PD-L1, anti-CTLA-4 antibody, or any other antibody or drug therapy for T cell co-stimulatory or checkpoint pathways, such as Inducible T-cell co-stimulator (ICOS) or agonists (e.g. CD40, CD137, GITR and OX40 etc).
• Subjects who received non-thoracic radiotherapy >30 Gy within 4 weeks prior to the first dose , or thoracic radiotherapy >30 Gy within 24 weeks prior to the first dose study drug.
• Other active malignancies within 2 years, except for locally treatable (manifested as cured) malignancies, such as basal or skin squamous cell carcinoma, superficial bladder cancer, cervical or breast carcinoma in situ.
• Subjects with active, known or suspected autoimmune disease, or a medical history of autoimmune disease,
• Subjects who require systemic corticosteroids (a dose equivalent to >10 mg/day prednisone) or other immunosuppressive drugs within 14 days prior to administration of AK104.
• Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
• Active or previously documented inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis or chronic diarrhea).
• Has interstitial lung disease or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management.
• Known history of active tuberculosis (TB).
• An active infection requiring systemic therapy.
• Subjects with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) DNA exceeding 1000 IU/ mL or active hepatitis C virus (HCV) should be excluded. Subjects with non-active HBsAg carriers, treated and stable hepatitis B (HBV DNA <1000 IU/ mL) , and cured hepatitis C can be enrolled. Subjects with positive HCV antibodies are eligible only if the HCV RNA test results are negative.
• Known history of testing positive for human immunodeficiency virus (HIV).
• Presence of meningeal metastasis, spinal cord compression, leptomeningeal disease or active brain metastasis.
• Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
• Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v5.0 Grade 0 or 1, or to levels dictated in the inclusion/exclusion criteria, with the exception of alopecia.
• Receipt of live vaccination within 30 days of planned treatment start, or plan to receive live vaccine during the study.
• Known history of server hypersensitivity to other monoclonal antibodies.
• Known severe allergic reactions to pemetrexed, paclitaxel, carboplatin or platinum-containing component, or their preventive medications.
• Known allergic reactions to any ingredients of AK104.
• Known history of substance abuse, or alcohol abuse
• Pregnant or lactating women.
• Any conditions that, in the investigator's opinion, may put subjects treated with the study drug at risks, or interfere with the evaluation of study drug or subject safety, or the interpretation of study results.

Contacts and Locations

Contacts

Contact: Xiaoping Jin, PhD; +86 (0760) 8987 3999; clinicaltrials@akesobio.com

Sponsors and Collaborators

Akeso

More Information

• Responsible Party: Akeso
• ClinicalTrials.gov Identifier: NCT04647344
• Other Study ID Numbers: AK104-207
• First Posted: November 30, 2020
• Last Update Posted: November 30, 2020
• Last Verified: November 2020

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Paclitaxel; Carboplatin; Pemetrexed; Antineoplastic Agents, Phytogenic; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Folic Acid Antagonists; Nucleic Acid Synthesis Inhibitors